← Human Trials & Peer-Reviewed Studies
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)
Plain-language guide to PMID 23258223 (2013): randomized controlled trial study of Goserelin and Degarelix.
Key Facts
- PMID
- 23258223
- Journal
- Urologia internationalis
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Anderson J et al. (8 authors)
- DOI
- 10.1159/000345423
- Registered trial
- NCT00831233
What This Study Did, in Plain Language
What Was Tested
Researchers studied Goserelin and Degarelix in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Goserelin group and the comparison group should start out alike.
The primary endpoint was change in International Prostate Symptom Score (IPSS) at week 12 compared with baseline.
What Was Measured
The subject headings attached to it are Analysis of Variance, Androgen Antagonists, Anilides, Early Termination of Clinical Trials, Europe, Goserelin and Lower Urinary Tract Symptoms.
What This Means in Plain Language
The paper is a randomized study of Goserelin and Degarelix.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (Urologia internationalis), a journal based in Switzerland.
More context: the Goserelin compound page and the Degarelix compound page, all human trials.
Our Notes on the Compounds
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Degarelix: A GnRH antagonist injection (Firmagon) for advanced prostate cancer that lowers testosterone within days without the initial surge seen with agonists.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.